Moderna Stock Slides as Phase 3 Cancer Vaccine Data Falls Short of Expectations

Moderna Inc. (MRNA) shares plunged 9.3% in pre-market trading as investors reacted to disappointing clinical trial data for its personalized mRNA cancer vaccine. The results, while clinically meaningful, fell below the efficacy levels seen in an earlier-stage study, triggering a multi-session sell-off and a wave of cautious analyst revisions.

Trial Results Trigger Sell-Off

The selling pressure stems from the Phase 3 INTerpath-001 trial results for intismeran autogene, a cancer vaccine developed with Merck. Data presented at the ESMO 2026 Congress showed that the vaccine, when combined with Merck's Keytruda, reduced the risk of melanoma recurrence or death by 42%.

While a significant outcome, this figure was lower than the 49% risk reduction observed in the preceding Phase 2b study. According to Investing.com, this gap between expectations and the final Phase 3 data sparked a classic "sell-the-news" reaction from investors, who are now recalibrating the potential of the company's oncology pipeline.

Analysts Turn More Cautious

Wall Street sentiment has shifted following the data release, with several analysts adjusting their outlook on the company. The more cautious stance has added to the downward pressure on the stock.

Ad

Key analyst actions reported include:

• Rothschild & Co Redburn: Downgraded Moderna to Sell from Neutral, citing valuation concerns after the stock's significant run-up.
• RBC Capital Markets: Described the Phase 3 results as being on the "low end" of expectations and showing a "deterioration" compared to earlier testing.
• Brookline Capital Markets: Trimmed its fiscal year 2030 earnings estimate for Moderna to $18.19 per share from a previous $19.11.

Market Context

The decline in Moderna's stock appears to be company-specific, as the broader market remained relatively stable. The S&P 500 and Dow Jones Industrial Average posted modest gains, indicating that macroeconomic factors were not the primary driver of the sell-off. The pre-market price of $181.44 is significantly below the stock's 52-week high of $254.48, reflecting the market's reassessment of its growth prospects.